Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Tesaro Inc (TSRO)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
[[ ctrl.chartTitle ]]
Full Chart

Fundamentals

See More
  • Market Capitalization, $K 7,006,332
  • Shares Outstanding, K 53,870
  • Annual Sales, $ 44,820 K
  • Annual Income, $ -387,470 K
  • 36-Month Beta 1.61
  • Price/Sales 154.96
  • Price/Cash Flow 0.00
  • Price/Book 13.52

Price Performance

See More
Period Period Low Period High Performance
1-Month
115.00 +10.17%
on 07/18/17
144.60 -12.38%
on 06/28/17
-14.33 (-10.16%)
since 06/27/17
3-Month
115.00 +10.17%
on 07/18/17
168.92 -24.99%
on 05/31/17
-19.91 (-13.58%)
since 04/27/17
52-Week
83.26 +52.17%
on 09/01/16
192.94 -34.33%
on 02/21/17
+33.32 (+35.68%)
since 07/27/16

Most Recent Stories

More News
Juno Therapeutics (JUNO) Q2 Earnings: Surprise in Store?

Although Juno Therapeutics' (JUNO) product portfolio shows a dearth of any revenue figures, the company's most advanced pipeline candidates -- JCAR017 and JCAR014 -- might drive its progress in Q2.

ESPR : 46.86 (-5.62%)
ZTS : 62.01 (-0.08%)
TSRO : 126.70 (-2.58%)
JUNO : 28.66 (-5.26%)
TESARO and Takeda Enter Into Exclusive Licensing Agreement to Develop and Commercialize Novel Cancer Therapy Niraparib in Japan

- Takeda's Rights Include all Potential Indications for Niraparib in Japan and Rights Excluding Prostate Cancer in South Korea, Taiwan, Russia and Australia

TSRO : 126.70 (-2.58%)
What's in Store for Agios Pharma (AGIO) in Q2 Earnings?

Encouraging performance of Agios' (AGIO) lead candidate Idhifa, which is under review in the U.S. for treatment of AML might drive the stock in Q2.

AGIO : 56.23 (-3.25%)
CELG : 134.15 (-2.61%)
ZTS : 62.01 (-0.08%)
TSRO : 126.70 (-2.58%)
What's in Store for Conatus (CNAT) this Earnings Season?

Conatus' (CNAT) aim to progress with its lead candidate emricasan might boost the stock in Q2 results, although the company's current portfolio shows no approved product and revenue generation.

CNAT : 5.68 (-4.70%)
ZTS : 62.01 (-0.08%)
NVS : 84.97 (+0.14%)
TSRO : 126.70 (-2.58%)
STA Signs Supply Agreement with TESARO

STA Pharmaceutical Co., Ltd. (STA) - a WuXi AppTec subsidiary and the leading open-access capability and technology platform for small molecule pharmaceutical development and manufacturing - announces...

TSRO : 126.70 (-2.58%)
Vertex Pharm has the Best Relative Performance in the Biotechnology Industry (VRTX, OPK, TSRO, ONCE, ALDR)

Here are the top 5 stocks in the Biotechnology industry ranked by performance. We compiled the trading activity from yesterday and then analyzed the industry looking for stocks that were outperforming....

ONCE : 70.29 (-3.29%)
ALDR : 10.65 (-4.91%)
VRTX : 156.19 (-4.42%)
OPK : 6.32 (-1.40%)
TSRO : 126.70 (-2.58%)
Clovis (CLVS) Focuses on Rubraca Launch and Label Expansion

We issued an updated research report on Boulder, CO-based Clovis Oncology, Inc. (CLVS) on Jul 12.

AZN : 28.88 (-14.91%)
CLVS : 92.25 (+5.51%)
TSRO : 126.70 (-2.58%)
PFE : 33.00 (+0.33%)
Is the Options Market Predicting a Spike in TESARO, Inc. (TSRO) Stock?

Options Market is Predicting a Spike in TESARO, Inc. (TSRO) Stock on the back of its surging implied volatility.

TSRO : 126.70 (-2.58%)
Stocks Under Scanner in the Biotech Space -- Achillion Pharma, Kite Pharma, Acorda Therapeutics, and Tesaro

If you want a Stock Review on ACHN, KITE, ACOR or TSRO then come over to http://dailystocktracker.com/register/ and sign up for your free customized report today. On Wednesday, July 05, 2017, the NASDAQ...

ACHN : 4.12 (-1.90%)
ACOR : 21.70 (-3.77%)
TSRO : 126.70 (-2.58%)
KITE : 108.88 (-2.12%)
TESARO Joins OCRFA as Presenting Sponsor of the 2017 Ovarian Cancer National Conference

TESARO, Inc. (NASDAQ:TSRO), an oncology-focused biopharmaceutical company, is proud to support the Ovarian Cancer Research Fund Alliance (OCRFA) as the Presenting Sponsor of the 2017 Ovarian Cancer National...

TSRO : 126.70 (-2.58%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 48% Sell with a Strengthening short term outlook on maintaining the current direction.

Longer term, the trend strength is Average. Long term indicators fully support a continuation of the trend.

See More

Business Summary

Tesaro, Inc. is an oncology-focused biopharmaceutical company for cancer patients. The Company's product portfolio consists of Rolapitant, a neurokinin-1 receptor antagonist for the prevention of chemotherapy induced nausea and vomiting, TSR-011, an orally available anaplastic lymphoma kinase inhibitor...

See More

Support & Resistance

2nd Resistance Point 134.51
1st Resistance Point 132.28
Last Price 126.70
1st Support Level 127.22
2nd Support Level 124.39

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.